| Literature DB >> 27651922 |
Adeline Ruyssen-Witrand1, Yannick Degboé2, A Cantagrel2, D Nigon3, C Lukas4, S Scaramuzzino5, Y Allanore6, O Vittecoq7, T Schaeverbeke8, J Morel4, J Sibilia9, A Cambon-Thomsen5, P Dieudé10, A Constantin2.
Abstract
OBJECTIVES: The RANK/RANKL/osteoprotegerin (OPG) system plays a central role in the pathogenesis of bone erosions in rheumatoid arthritis (RA). The aim of this study was to test the association between 11 single-nucleotide polymorphisms (SNPs) located on RANK, RANKL and OPG genes and anticitrullinated peptide antibody (ACPA) presence or erosions in RA. PATIENTS: This work was performed on three independent samples of French patients with RA: the Etude de Suivi des PolyArthrites Indifférenciées Récentes (ESPOIR) (n=632), Rangueil Midi-Pyrénées (RMP) (n=249) and French Rheumatoid Arthritis Genetic Consortium (FRAGC) (n=590) cohorts. Genotyping: the genotyping of 11 SNPs located on RANK, RANKL and OPG were performed by PCR. STATISTICAL ANALYSES: The association between the genotypes with ACPA or erosions was first tested in the ESPOIR cohort using a χ(2) test and, in the case of significant association, replicated in the RMP and FRACG cohorts. A meta-analysis on the three cohorts was performed using the Mantel-Haenszel method.Entities:
Keywords: Ant-CCP; Gene Polymorphism; Rheumatoid Arthritis
Year: 2016 PMID: 27651922 PMCID: PMC5020667 DOI: 10.1136/rmdopen-2015-000226
Source DB: PubMed Journal: RMD Open ISSN: 2056-5933
Patient characteristics from all three data sets
| ESPOIR | RMP | FRAGC | |
|---|---|---|---|
| Age at disease onset, years, med (IQR) | 50 (39–57) | 50 (39–61) | 45 (34–55) |
| Female (%) | 490 (78) | 188 (75) | 448 (76) |
| Disease duration, year, med (IQR) | 0.4 (0.2–0.6) | 0.6 (0.3–0.9) | 9.0 (4.7–18.0) |
| ACPA, number (%)* | 308 (49) | 177 (73) | 311 (61) |
| Patients with a ESS≥1, number (%)† | 219 (37) | 92 (39) | 366 (67) |
*Number of missing data: ESPOIR: n=0, RMP: n=8, FRAGC: n=76.
†Number of missing radiographs: ESPOIR: n=33, RMP: n=12, FRAGC: n=47.
ACPA, anticitrullinated peptide antibodies; ESPOIR, Etude de Suivi des PolyArthrites Indifférenciées Récentes; ESS, Erosion Sharp Score; FRAGC, French Rheumatoid Arthritis Genetic Consortium; Med, median; RMP, Rangueil Midi-Pyrénées.
Association of the SNPs located on RANK, RANKL and OPG; and ACPA presence or erosions in 632 patients in the ESPOIR cohort
| Rs | Genotypes | Association with ACPA | Association with erosions | ||||
|---|---|---|---|---|---|---|---|
| Number of ACPA+ (%) | χ2 test p value | Trend-test p value | Number of patients with erosions (%) | χ2 test p value | Trend-test p value | ||
| rs8086340 | GG | 106 (56.1) | 0.02 | 0.02 | 68 (37.8) | 0.8 | 0.8 |
| CG | 148 (46.7) | 108 (35.5) | |||||
| CC | 49 (40.8) | 42 (38.2) | |||||
| rs1805034 | TT | 103 (51.8) | 0.4 | 0.4 | 63 (32.8) | 0.2 | 0.2 |
| CT | 154 (48.3) | 121 (40.6) | |||||
| CC | 46 (43.8) | 34 (33.7) | |||||
| rs35211496 | TT | 18 (56.3) | 0.3 | 0.3 | 11 (35.5) | 1.0 | 1.0 |
| CT | 98 (51.8) | 68 (37.6) | |||||
| CC | 187 (46.3) | 139 (36.6) | |||||
| rs2277438 | GG | 7 (63.6) | 0.3 | 0.3 | 2 (18.2) | 0.2 | 0.2 |
| AG | 80 (44.9) | 66 (40.2) | |||||
| AA | 217 (49.7) | 147 (35.1) | |||||
| rs1054016 | GG | 101 (45.7) | 0.04 | 0.05 | 81 (38.9) | 0.3 | 0.2 |
| GT | 142 (46.4) | 109 (37.3) | |||||
| TT | 57 (60.0) | 27 (29.7) | |||||
| rs7325635 | GG | 101 (46.3) | 0.04 | 0.05 | 81 (39.5) | 0.06 | 0.05 |
| AG | 140 (46.5) | 109 (38.0) | |||||
| AA | 64 (59.8) | 27 (26.5) | |||||
| rs7984870 | GG | 88 (45.4) | 0.03 | 0.03 | 73 (39.7) | 0.1 | 0.06 |
| CG | 142 (46.0) | 111 (38.0) | |||||
| CC | 74 (59.2) | 34 (38.3) | |||||
| rs2073618 | CC | 82 (50.0) | 0.8 | 0.8 | 67 (42.4) | 0.03 | 0.03 |
| CG | 145 (49.0) | 106 (38.1) | |||||
| GG | 80 (46.8) | 46 (28.4) | |||||
| rs2073617 | TT | 79 (43.9) | 0.3 | 0.3 | 52 (30.6) | 0.2 | 0.2 |
| CT | 146 (50.2) | 106 (38.7) | |||||
| CC | 74 (51.4) | 54 (38.9) | |||||
| rs10955911 | GG | 219 (51.3) | 0.2 | 0.2 | 159 (39.0) | 0.1 | 0.1 |
| AG | 76 (43.2) | 54 (33.1) | |||||
| AA | 12 (46.4) | 6 (22.2) | |||||
| rs1485305 | TT | 86 (50.0) | 0.8 | 0.8 | 65 (39.4) | 0.3 | 0.3 |
| AT | 144 (48.00) | 107 (38.1) | |||||
| AA | 65 (46.4) | 42 (31.1) | |||||
ACPA, anticitrullinated peptide antibodies; OPG, osteoprotegerin; RANK, receptor activator of nuclear factor κ B; RANKL, receptor activator of nuclear factor κ B ligand; SNP, single-nucleotide polymorphisms.
Results of the meta-analysis on the three cohorts assessing the association of a SNP on RANK, a haplotype on RANKL with ACPA; and a SNP on RANKL, a SNP on OPG with erosions
| ESPOIR | FRAGC | RMP | Meta-analysis | ||
|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | p Value | |
| Association with ACPA | |||||
| 0.64 (0.45 to 0.91) | 0.71 (0.47 to 1.06) | 0.46 (0.23 to 0.92) | 0.64 (0.50 to 0.81) | 0.0003 | |
| 0.58 (0.38 to 0.89) | 0.60 (0.34 to 1.03) | 0.93 (0.43 to 1.98) | 0.63 (0.46 to 0.86) | 0.003 | |
| Association with erosions | |||||
| 1.75 (1.18 to 2.82) | 0.67 (0.39 to 1.16) | 0.50 (0.26 to 0.98) | 0.97 (0.71 to 1.32) | 0.85 | |
| 0.72 (0.49 to 1.04) | 0.49 (0.31 to 0.78) | 1.10 (0.59 to 2.05) | 0.68 (0.52 to 0.88) | 0.004 | |
ACPA, anticitrullinated peptide antibodies; RANK, receptor activator of nuclear factor κ B; RANKL, receptor activator of nuclear factor κ B ligand; OPG, osteoprotegerin; SNP, single-nucleotide polymorphisms.